A value-driven review of the Ka-Bar Turok arguing its case as the best survival knife under $100. Heavy snow warning as 11 inches could drop Wife of teacher killed in senior prank makes unexpected ...

An in-depth review of the Fallkniven A1 explaining why it stands out as a favorite stainless steel survival knife. Mamdani’s 'white supremacist' comment after terrorist attack draws MAGA backlash 6 ...

Knife pricing is undoubtedly confusing. It’s possible to find Damascus steel knives with hand-carved wooden handles for upwards of a thousand dollars. Meanwhile, Amazon is full of unheard-of brands ...

Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on ...

Eli Lilly's success rate in clinical trials was phenomenal last year. The drugmaker has made a big name for itself in diabetes and weight loss. But it's also proving innovative even beyond its core ...

The LIBRETTO-432 trial results showed that selpercatinib significantly reduced the risk of disease recurrence or death in patients with RET fusion-positive non-small cell lung cancer. This trial is ...

The Eli Lilly logo appears on a laptop computer screen in this photo illustration in Athens, Greece, on February 9, 2026. Vaccine manufacturers play a central role in global public health, investing ...

Lilly agreed to purchase biotech Orna Therapeutics. Orna's drug candidate treats diseases in a novel way. Lilly has been busy this year filling its drug pipeline. In fact, last year Lilly's medication ...

Eli Lilly is heading back to its regular Chinese collaborator Innovent Biologics with $350 million in upfront cash to collaborate on new meds for patients with cancer or immune disorders. The ...

CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...

Eli Lilly has struck a deal to buy genetic-medicine biotechnology company Orna Therapeutics for up to $2.4 billion in cash. Eli Lilly on Monday said Orna, which is dedicated to engineering immune ...